▶ 調査レポート

世界の骨髄異形成症候群治療市場(~2028年):同種幹細胞移植、自家幹細胞移植

• 英文タイトル:Global Myelodysplastic Syndrome Treatment Market Insights, Forecast to 2028

Global Myelodysplastic Syndrome Treatment Market Insights, Forecast to 2028「世界の骨髄異形成症候群治療市場(~2028年):同種幹細胞移植、自家幹細胞移植」(市場規模、市場予測)調査レポートです。• レポートコード:MRC2Q12-16803
• 出版社/出版日:QYResearch / 2022年12月
• レポート形態:英文、PDF、113ページ
• 納品方法:Eメール(納期:3営業日)
• 産業分類:医療
• 販売価格(消費税別)
  Single User¥725,200 (USD4,900)▷ お問い合わせ
  Enterprise License¥1,450,400 (USD9,800)▷ お問い合わせ
• ご注文方法:お問い合わせフォーム記入又はEメールでご連絡ください。
• お支払方法:銀行振込(納品後、ご請求書送付)
レポート概要
新型コロナウイルス感染症とロシア・ウクライナ戦争の影響により、骨髄異形成症候群治療のグローバル市場は 2022にxxxドルと推定され、2028年までにxxxドルの規模に達し、2022年から2028年の予測期間中にxxx%のCAGRで成長すると予測されています。
骨髄異形成症候群治療のアメリカ市場は、2023年から2028年の予測期間中にxxx%のCAGRで、2022年xxxドルから2028年xxxドルに達すると推定されています。
骨髄異形成症候群治療の中国市場は、2023年から2028年の予測期間中にxxx%のCAGRで、2022年xxxドルから2028年xxxドルに達すると推定されています。
骨髄異形成症候群治療のヨーロッパ市場は、2023年から2028年の予測期間中にxxx%のCAGRで、2022年xxxドルから2028年xxxドルに達すると推定されています。

生産面において、本レポートは2017年から2022年までの骨髄異形成症候群治療の生産、成長率、メーカー別市場シェア、地域別市場シェア、および2028年までの予測を調査しています。販売面において、本レポートは2017年から2022年までの地域別、企業別、タイプ別、アプリケーション別の骨髄異形成症候群治療の売上および2028年までの予測に焦点を当てています。

骨髄異形成症候群治療のグローバル主要企業には、AbbVie Inc.、Bristol-Myers Squibb、Accord Healthcare、Jazz Pharmaceuticals Inc.、Novartis AG、Lupin Pharmaceuticals、Otsuka America Pharmaceutical Inc.、Onconova Therapeutics、Takeda Pharmaceutical Company Limited、Astex Pharmaceuticals, Inc.、Amgen Inc.、Hikma Pharmaceuticals PLCなどがあります。2021年、世界のトップ5プレイヤーは売上ベースで約xxx%の市場シェアを占めています。

骨髄異形成症候群治療市場は、タイプとアプリケーションによって区分されます。世界の骨髄異形成症候群治療市場のプレーヤー、利害関係者、およびその他の参加者は、当レポートを有益なリソースとして使用することで優位に立つことができます。セグメント分析は、2017年~2028年期間のタイプ別およびアプリケーション別の販売量、売上、予測に焦点を当てています。

【タイプ別セグメント】
同種幹細胞移植、自家幹細胞移植

【アプリケーション別セグメント】
病院、クリニック、その他

【掲載地域】
北米:アメリカ、カナダ
ヨーロッパ:ドイツ、フランス、イギリス、イタリア、ロシア
アジア太平洋:日本、中国、韓国、インド、オーストラリア、台湾、インドネシア、タイ、マレーシア
中南米:メキシコ、ブラジル、アルゼンチン
中東・アフリカ:トルコ、サウジアラビア、UAE

【目次(一部)】

・調査の範囲
- 骨髄異形成症候群治療製品概要
- タイプ別市場(同種幹細胞移植、自家幹細胞移植)
- アプリケーション別市場(病院、クリニック、その他)
- 調査の目的
・エグゼクティブサマリー
- 世界の骨髄異形成症候群治療販売量予測2017-2028
- 世界の骨髄異形成症候群治療売上予測2017-2028
- 骨髄異形成症候群治療の地域別販売量
- 骨髄異形成症候群治療の地域別売上
- 北米市場
- ヨーロッパ市場
- アジア太平洋市場
- 中南米市場
- 中東・アフリカ市場
・メーカーの競争状況
- 主要メーカー別骨髄異形成症候群治療販売量
- 主要メーカー別骨髄異形成症候群治療売上
- 主要メーカー別骨髄異形成症候群治療価格
- 競争状況の分析
- 企業M&A動向
・タイプ別市場規模(同種幹細胞移植、自家幹細胞移植)
- 骨髄異形成症候群治療のタイプ別販売量
- 骨髄異形成症候群治療のタイプ別売上
- 骨髄異形成症候群治療のタイプ別価格
・アプリケーション別市場規模(病院、クリニック、その他)
- 骨髄異形成症候群治療のアプリケーション別販売量
- 骨髄異形成症候群治療のアプリケーション別売上
- 骨髄異形成症候群治療のアプリケーション別価格
・北米市場
- 北米の骨髄異形成症候群治療市場規模(タイプ別、アプリケーション別)
- 主要国別の骨髄異形成症候群治療市場規模(アメリカ、カナダ)
・ヨーロッパ市場
- ヨーロッパの骨髄異形成症候群治療市場規模(タイプ別、アプリケーション別)
- 主要国別の骨髄異形成症候群治療市場規模(ドイツ、フランス、イギリス、イタリア、ロシア)
・アジア太平洋市場
- アジア太平洋の骨髄異形成症候群治療市場規模(タイプ別、アプリケーション別)
- 主要国別の骨髄異形成症候群治療市場規模(日本、中国、韓国、インド、オーストラリア、台湾、インドネシア、タイ、マレーシア)
・中南米市場
- 中南米の骨髄異形成症候群治療市場規模(タイプ別、アプリケーション別)
- 主要国別の骨髄異形成症候群治療市場規模(メキシコ、ブラジル、アルゼンチン)
・中東・アフリカ市場
- 中東・アフリカの骨髄異形成症候群治療市場規模(タイプ別、アプリケーション別)
- 主要国別の骨髄異形成症候群治療市場規模(トルコ、サウジアラビア)
・企業情報
AbbVie Inc.、Bristol-Myers Squibb、Accord Healthcare、Jazz Pharmaceuticals Inc.、Novartis AG、Lupin Pharmaceuticals、Otsuka America Pharmaceutical Inc.、Onconova Therapeutics、Takeda Pharmaceutical Company Limited、Astex Pharmaceuticals, Inc.、Amgen Inc.、Hikma Pharmaceuticals PLC
・産業チェーン及び販売チャネル分析
- 骨髄異形成症候群治療の産業チェーン分析
- 骨髄異形成症候群治療の原材料
- 骨髄異形成症候群治療の生産プロセス
- 骨髄異形成症候群治療の販売及びマーケティング
- 骨髄異形成症候群治療の主要顧客
・マーケットドライバー、機会、課題、リスク要因分析
- 骨髄異形成症候群治療の産業動向
- 骨髄異形成症候群治療のマーケットドライバー
- 骨髄異形成症候群治療の課題
- 骨髄異形成症候群治療の阻害要因
・主な調査結果

Market Analysis and Insights: Global Myelodysplastic Syndrome Treatment Market
The global Myelodysplastic Syndrome Treatment market size is projected to reach US$ million by 2028, from US$ million in 2021, at a CAGR of % during 2022-2028.
Fully considering the economic change by this health crisis, Allogeneic Stem Cell Transplantation accounting for % of the Myelodysplastic Syndrome Treatment global market in 2021, is projected to value US$ million by 2028, growing at a revised % CAGR from 2022 to 2028. While Hospitals segment is altered to an % CAGR throughout this forecast period.
China Myelodysplastic Syndrome Treatment market size is valued at US$ million in 2021, while the North America and Europe Myelodysplastic Syndrome Treatment are US$ million and US$ million, severally. The proportion of the North America is % in 2021, while China and Europe are % and % respectively, and it is predicted that China proportion will reach % in 2028, trailing a CAGR of % through the analysis period 2022-2028. Japan, South Korea, and Southeast Asia are noteworthy markets in Asia, with CAGR %, %, and % respectively for the next 6-year period. As for the Europe Myelodysplastic Syndrome Treatment landscape, Germany is projected to reach US$ million by 2028 trailing a CAGR of % over the forecast period 2022-2028.
With industry-standard accuracy in analysis and high data integrity, the report makes a brilliant attempt to unveil key opportunities available in the global Myelodysplastic Syndrome Treatment market to help players in achieving a strong market position. Buyers of the report can access verified and reliable market forecasts, including those for the overall size of the global Myelodysplastic Syndrome Treatment market in terms of revenue.
Overall, the report proves to be an effective tool that players can use to gain a competitive edge over their competitors and ensure lasting success in the global Myelodysplastic Syndrome Treatment market. All of the findings, data, and information provided in the report are validated and revalidated with the help of trustworthy sources. The analysts who have authored the report took a unique and industry-best research and analysis approach for an in-depth study of the global Myelodysplastic Syndrome Treatment market.
Global Myelodysplastic Syndrome Treatment Scope and Market Size
Myelodysplastic Syndrome Treatment market is segmented by players, region (country), by Treatment Method and by Application. Players, stakeholders, and other participants in the global Myelodysplastic Syndrome Treatment market will be able to gain the upper hand as they use the report as a powerful resource. The segmental analysis focuses on revenue and forecast by Treatment Method and by Application for the period 2017-2028.
Segment by Treatment Method
Allogeneic Stem Cell Transplantation
Autologous Stem Cell Transplantation
Segment by Application
Hospitals
Clinics
Others
By Company
AbbVie Inc.
Bristol-Myers Squibb
Accord Healthcare
Jazz Pharmaceuticals Inc.
Novartis AG
Lupin Pharmaceuticals
Otsuka America Pharmaceutical Inc.
Onconova Therapeutics
Takeda Pharmaceutical Company Limited
Astex Pharmaceuticals, Inc.
Amgen Inc.
Hikma Pharmaceuticals PLC
By Region
North America
United States
Canada
Europe
Germany
France
UK
Italy
Russia
Nordic Countries
Rest of Europe
Asia-Pacific
China
Japan
South Korea
Southeast Asia
India
Australia
Rest of Asia
Latin America
Mexico
Brazil
Rest of Latin America
Middle East & Africa
Turkey
Saudi Arabia
UAE
Rest of MEA

レポート目次

1 Report Business Overview
1.1 Study Scope
1.2 Market Analysis by Treatment Method
1.2.1 Global Myelodysplastic Syndrome Treatment Market Size Growth Rate by Treatment Method, 2017 VS 2021 VS 2028
1.2.2 Allogeneic Stem Cell Transplantation
1.2.3 Autologous Stem Cell Transplantation
1.3 Market by Application
1.3.1 Global Myelodysplastic Syndrome Treatment Market Size Growth Rate by Application, 2017 VS 2021 VS 2028
1.3.2 Hospitals
1.3.3 Clinics
1.3.4 Others
1.4 Study Objectives
1.5 Years Considered
2 Global Growth Trends
2.1 Global Myelodysplastic Syndrome Treatment Market Perspective (2017-2028)
2.2 Myelodysplastic Syndrome Treatment Growth Trends by Region
2.2.1 Myelodysplastic Syndrome Treatment Market Size by Region: 2017 VS 2021 VS 2028
2.2.2 Myelodysplastic Syndrome Treatment Historic Market Size by Region (2017-2022)
2.2.3 Myelodysplastic Syndrome Treatment Forecasted Market Size by Region (2023-2028)
2.3 Myelodysplastic Syndrome Treatment Market Dynamics
2.3.1 Myelodysplastic Syndrome Treatment Industry Trends
2.3.2 Myelodysplastic Syndrome Treatment Market Drivers
2.3.3 Myelodysplastic Syndrome Treatment Market Challenges
2.3.4 Myelodysplastic Syndrome Treatment Market Restraints
3 Competition Landscape by Key Players
3.1 Global Top Myelodysplastic Syndrome Treatment Players by Revenue
3.1.1 Global Top Myelodysplastic Syndrome Treatment Players by Revenue (2017-2022)
3.1.2 Global Myelodysplastic Syndrome Treatment Revenue Market Share by Players (2017-2022)
3.2 Global Myelodysplastic Syndrome Treatment Market Share by Company Type (Tier 1, Tier 2, and Tier 3)
3.3 Players Covered: Ranking by Myelodysplastic Syndrome Treatment Revenue
3.4 Global Myelodysplastic Syndrome Treatment Market Concentration Ratio
3.4.1 Global Myelodysplastic Syndrome Treatment Market Concentration Ratio (CR5 and HHI)
3.4.2 Global Top 10 and Top 5 Companies by Myelodysplastic Syndrome Treatment Revenue in 2021
3.5 Myelodysplastic Syndrome Treatment Key Players Head office and Area Served
3.6 Key Players Myelodysplastic Syndrome Treatment Product Solution and Service
3.7 Date of Enter into Myelodysplastic Syndrome Treatment Market
3.8 Mergers & Acquisitions, Expansion Plans
4 Myelodysplastic Syndrome Treatment Breakdown Data by Treatment Method
4.1 Global Myelodysplastic Syndrome Treatment Historic Market Size by Treatment Method (2017-2022)
4.2 Global Myelodysplastic Syndrome Treatment Forecasted Market Size by Treatment Method (2023-2028)
5 Myelodysplastic Syndrome Treatment Breakdown Data by Application
5.1 Global Myelodysplastic Syndrome Treatment Historic Market Size by Application (2017-2022)
5.2 Global Myelodysplastic Syndrome Treatment Forecasted Market Size by Application (2023-2028)
6 North America
6.1 North America Myelodysplastic Syndrome Treatment Market Size (2017-2028)
6.2 North America Myelodysplastic Syndrome Treatment Market Size by Treatment Method
6.2.1 North America Myelodysplastic Syndrome Treatment Market Size by Treatment Method (2017-2022)
6.2.2 North America Myelodysplastic Syndrome Treatment Market Size by Treatment Method (2023-2028)
6.2.3 North America Myelodysplastic Syndrome Treatment Market Share by Treatment Method (2017-2028)
6.3 North America Myelodysplastic Syndrome Treatment Market Size by Application
6.3.1 North America Myelodysplastic Syndrome Treatment Market Size by Application (2017-2022)
6.3.2 North America Myelodysplastic Syndrome Treatment Market Size by Application (2023-2028)
6.3.3 North America Myelodysplastic Syndrome Treatment Market Share by Application (2017-2028)
6.4 North America Myelodysplastic Syndrome Treatment Market Size by Country
6.4.1 North America Myelodysplastic Syndrome Treatment Market Size by Country (2017-2022)
6.4.2 North America Myelodysplastic Syndrome Treatment Market Size by Country (2023-2028)
6.4.3 United States
6.4.4 Canada
7 Europe
7.1 Europe Myelodysplastic Syndrome Treatment Market Size (2017-2028)
7.2 Europe Myelodysplastic Syndrome Treatment Market Size by Treatment Method
7.2.1 Europe Myelodysplastic Syndrome Treatment Market Size by Treatment Method (2017-2022)
7.2.2 Europe Myelodysplastic Syndrome Treatment Market Size by Treatment Method (2023-2028)
7.2.3 Europe Myelodysplastic Syndrome Treatment Market Share by Treatment Method (2017-2028)
7.3 Europe Myelodysplastic Syndrome Treatment Market Size by Application
7.3.1 Europe Myelodysplastic Syndrome Treatment Market Size by Application (2017-2022)
7.3.2 Europe Myelodysplastic Syndrome Treatment Market Size by Application (2023-2028)
7.3.3 Europe Myelodysplastic Syndrome Treatment Market Share by Application (2017-2028)
7.4 Europe Myelodysplastic Syndrome Treatment Market Size by Country
7.4.1 Europe Myelodysplastic Syndrome Treatment Market Size by Country (2017-2022)
7.4.2 Europe Myelodysplastic Syndrome Treatment Market Size by Country (2023-2028)
7.4.3 Germany
7.4.4 France
7.4.5 U.K.
7.4.6 Italy
7.4.7 Russia
7.4.8 Nordic Countries
8 Asia-Pacific
8.1 Asia-Pacific Myelodysplastic Syndrome Treatment Market Size (2017-2028)
8.2 Asia-Pacific Myelodysplastic Syndrome Treatment Market Size by Treatment Method
8.2.1 Asia-Pacific Myelodysplastic Syndrome Treatment Market Size by Treatment Method (2017-2022)
8.2.2 Asia-Pacific Myelodysplastic Syndrome Treatment Market Size by Treatment Method (2023-2028)
8.2.3 Asia-Pacific Myelodysplastic Syndrome Treatment Market Share by Treatment Method (2017-2028)
8.3 Asia-Pacific Myelodysplastic Syndrome Treatment Market Size by Application
8.3.1 Asia-Pacific Myelodysplastic Syndrome Treatment Market Size by Application (2017-2022)
8.3.2 Asia-Pacific Myelodysplastic Syndrome Treatment Market Size by Application (2023-2028)
8.3.3 Asia-Pacific Myelodysplastic Syndrome Treatment Market Share by Application (2017-2028)
8.4 Asia-Pacific Myelodysplastic Syndrome Treatment Market Size by Region
8.4.1 Asia-Pacific Myelodysplastic Syndrome Treatment Market Size by Region (2017-2022)
8.4.2 Asia-Pacific Myelodysplastic Syndrome Treatment Market Size by Region (2023-2028)
8.4.3 China
8.4.4 Japan
8.4.5 South Korea
8.4.6 Southeast Asia
8.4.7 India
8.4.8 Australia
9 Latin America
9.1 Latin America Myelodysplastic Syndrome Treatment Market Size (2017-2028)
9.2 Latin America Myelodysplastic Syndrome Treatment Market Size by Treatment Method
9.2.1 Latin America Myelodysplastic Syndrome Treatment Market Size by Treatment Method (2017-2022)
9.2.2 Latin America Myelodysplastic Syndrome Treatment Market Size by Treatment Method (2023-2028)
9.2.3 Latin America Myelodysplastic Syndrome Treatment Market Share by Treatment Method (2017-2028)
9.3 Latin America Myelodysplastic Syndrome Treatment Market Size by Application
9.3.1 Latin America Myelodysplastic Syndrome Treatment Market Size by Application (2017-2022)
9.3.2 Latin America Myelodysplastic Syndrome Treatment Market Size by Application (2023-2028)
9.3.3 Latin America Myelodysplastic Syndrome Treatment Market Share by Application (2017-2028)
9.4 Latin America Myelodysplastic Syndrome Treatment Market Size by Country
9.4.1 Latin America Myelodysplastic Syndrome Treatment Market Size by Country (2017-2022)
9.4.2 Latin America Myelodysplastic Syndrome Treatment Market Size by Country (2023-2028)
9.4.3 Mexico
9.4.4 Brazil
10 Middle East & Africa
10.1 Middle East & Africa Myelodysplastic Syndrome Treatment Market Size (2017-2028)
10.2 Middle East & Africa Myelodysplastic Syndrome Treatment Market Size by Treatment Method
10.2.1 Middle East & Africa Myelodysplastic Syndrome Treatment Market Size by Treatment Method (2017-2022)
10.2.2 Middle East & Africa Myelodysplastic Syndrome Treatment Market Size by Treatment Method (2023-2028)
10.2.3 Middle East & Africa Myelodysplastic Syndrome Treatment Market Share by Treatment Method (2017-2028)
10.3 Middle East & Africa Myelodysplastic Syndrome Treatment Market Size by Application
10.3.1 Middle East & Africa Myelodysplastic Syndrome Treatment Market Size by Application (2017-2022)
10.3.2 Middle East & Africa Myelodysplastic Syndrome Treatment Market Size by Application (2023-2028)
10.3.3 Middle East & Africa Myelodysplastic Syndrome Treatment Market Share by Application (2017-2028)
10.4 Middle East & Africa Myelodysplastic Syndrome Treatment Market Size by Country
10.4.1 Middle East & Africa Myelodysplastic Syndrome Treatment Market Size by Country (2017-2022)
10.4.2 Middle East & Africa Myelodysplastic Syndrome Treatment Market Size by Country (2023-2028)
10.4.3 Turkey
10.4.4 Saudi Arabia
10.4.5 UAE
11 Key Players Profiles
11.1 AbbVie Inc.
11.1.1 AbbVie Inc. Company Details
11.1.2 AbbVie Inc. Business Overview
11.1.3 AbbVie Inc. Myelodysplastic Syndrome Treatment Introduction
11.1.4 AbbVie Inc. Revenue in Myelodysplastic Syndrome Treatment Business (2017-2022)
11.1.5 AbbVie Inc. Recent Developments
11.2 Bristol-Myers Squibb
11.2.1 Bristol-Myers Squibb Company Details
11.2.2 Bristol-Myers Squibb Business Overview
11.2.3 Bristol-Myers Squibb Myelodysplastic Syndrome Treatment Introduction
11.2.4 Bristol-Myers Squibb Revenue in Myelodysplastic Syndrome Treatment Business (2017-2022)
11.2.5 Bristol-Myers Squibb Recent Developments
11.3 Accord Healthcare
11.3.1 Accord Healthcare Company Details
11.3.2 Accord Healthcare Business Overview
11.3.3 Accord Healthcare Myelodysplastic Syndrome Treatment Introduction
11.3.4 Accord Healthcare Revenue in Myelodysplastic Syndrome Treatment Business (2017-2022)
11.3.5 Accord Healthcare Recent Developments
11.4 Jazz Pharmaceuticals Inc.
11.4.1 Jazz Pharmaceuticals Inc. Company Details
11.4.2 Jazz Pharmaceuticals Inc. Business Overview
11.4.3 Jazz Pharmaceuticals Inc. Myelodysplastic Syndrome Treatment Introduction
11.4.4 Jazz Pharmaceuticals Inc. Revenue in Myelodysplastic Syndrome Treatment Business (2017-2022)
11.4.5 Jazz Pharmaceuticals Inc. Recent Developments
11.5 Novartis AG
11.5.1 Novartis AG Company Details
11.5.2 Novartis AG Business Overview
11.5.3 Novartis AG Myelodysplastic Syndrome Treatment Introduction
11.5.4 Novartis AG Revenue in Myelodysplastic Syndrome Treatment Business (2017-2022)
11.5.5 Novartis AG Recent Developments
11.6 Lupin Pharmaceuticals
11.6.1 Lupin Pharmaceuticals Company Details
11.6.2 Lupin Pharmaceuticals Business Overview
11.6.3 Lupin Pharmaceuticals Myelodysplastic Syndrome Treatment Introduction
11.6.4 Lupin Pharmaceuticals Revenue in Myelodysplastic Syndrome Treatment Business (2017-2022)
11.6.5 Lupin Pharmaceuticals Recent Developments
11.7 Otsuka America Pharmaceutical Inc.
11.7.1 Otsuka America Pharmaceutical Inc. Company Details
11.7.2 Otsuka America Pharmaceutical Inc. Business Overview
11.7.3 Otsuka America Pharmaceutical Inc. Myelodysplastic Syndrome Treatment Introduction
11.7.4 Otsuka America Pharmaceutical Inc. Revenue in Myelodysplastic Syndrome Treatment Business (2017-2022)
11.7.5 Otsuka America Pharmaceutical Inc. Recent Developments
11.8 Onconova Therapeutics
11.8.1 Onconova Therapeutics Company Details
11.8.2 Onconova Therapeutics Business Overview
11.8.3 Onconova Therapeutics Myelodysplastic Syndrome Treatment Introduction
11.8.4 Onconova Therapeutics Revenue in Myelodysplastic Syndrome Treatment Business (2017-2022)
11.8.5 Onconova Therapeutics Recent Developments
11.9 Takeda Pharmaceutical Company Limited
11.9.1 Takeda Pharmaceutical Company Limited Company Details
11.9.2 Takeda Pharmaceutical Company Limited Business Overview
11.9.3 Takeda Pharmaceutical Company Limited Myelodysplastic Syndrome Treatment Introduction
11.9.4 Takeda Pharmaceutical Company Limited Revenue in Myelodysplastic Syndrome Treatment Business (2017-2022)
11.9.5 Takeda Pharmaceutical Company Limited Recent Developments
11.10 Astex Pharmaceuticals, Inc.
11.10.1 Astex Pharmaceuticals, Inc. Company Details
11.10.2 Astex Pharmaceuticals, Inc. Business Overview
11.10.3 Astex Pharmaceuticals, Inc. Myelodysplastic Syndrome Treatment Introduction
11.10.4 Astex Pharmaceuticals, Inc. Revenue in Myelodysplastic Syndrome Treatment Business (2017-2022)
11.10.5 Astex Pharmaceuticals, Inc. Recent Developments
11.11 Amgen Inc.
11.11.1 Amgen Inc. Company Details
11.11.2 Amgen Inc. Business Overview
11.11.3 Amgen Inc. Myelodysplastic Syndrome Treatment Introduction
11.11.4 Amgen Inc. Revenue in Myelodysplastic Syndrome Treatment Business (2017-2022)
11.11.5 Amgen Inc. Recent Developments
11.12 Hikma Pharmaceuticals PLC
11.12.1 Hikma Pharmaceuticals PLC Company Details
11.12.2 Hikma Pharmaceuticals PLC Business Overview
11.12.3 Hikma Pharmaceuticals PLC Myelodysplastic Syndrome Treatment Introduction
11.12.4 Hikma Pharmaceuticals PLC Revenue in Myelodysplastic Syndrome Treatment Business (2017-2022)
11.12.5 Hikma Pharmaceuticals PLC Recent Developments
12 Analyst’s Viewpoints/Conclusions
13 Appendix
13.1 Research Methodology
13.1.1 Methodology/Research Approach
13.1.2 Data Source
13.2 Author Details
13.3 Disclaimer